Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months

Inclusion Criteria:

• Healthy male and female child as established by medical history and clinicalexamination at enrollment.

• Age: 9-11 months (inclusive) at the time of enrollment

• Parent's/legally acceptable representative's (LAR) ability to read and willingnessto provide written informed consent as per the ethical and regulatory requirementsof the site.

• Parent confirms intention to stay in the study area for the study duration, bringtheir child in for the required study visits or to accept a home visit by the studystaff.

Exclusion Criteria:

• Presence of fever (defined as axillary temperature ≥ 37.5°C) (temporary exclusionuntil recovery)

• Acute disease of moderate to severe intensity at the time of enrollment (temporaryexclusion until recovery)

• Use of antipyretics within the last 72 hours prior to enrolment (temporary exclusionuntil recovery)

• Prior (within 6 months) or concurrent participation in another interventionalclinical trial during the study

• Presence of severe malnutrition (weight-for-height z-score < -3SD median)

• Positive test for any of the following: HIV, hepatitis B, hepatitis C and syphilis

• Presence of any systemic disorder (cardiovascular, pulmonary, hepatic, renal,gastrointestinal, hematological (including severe anemia), endocrine, immunological,dermatological, neurological, cancer, or autoimmune disease) as determined bymedical history and / or physical examination which would compromise theparticipant's health or is likely to result in nonconformance to the protocol.

• Known or suspected impairment of immunological function based on medical history andphysical examination.

• Prior receipt or intent to receive measles, mumps, rubella, or yellowfever-containing vaccine during the study vaccination and follow up period up to Day 85 outside the study center.

• Receipt of any vaccine (except OPV and inactivated influenza) within 4 weeks of theday of study vaccination or intent to receive any within 6 weeks after studyvaccination.

• Receipt of immunoglobulin therapy and / or blood products in the past 9 months orplanned administration during the study period

• Receipt of any immune-modifying or immunosuppressant drugs prior to the first studyvaccine dose or planned use during the study. A chronic oral or parenteral use (defined as more than 14 days) of high dose corticosteroids (defined as ≥2 mg/kg ofbody weight or ≥20 mg/day of prednisone or equivalent for persons who weigh >10 kg)will be exclusionary for the study. Children on inhaled or topical steroids may bepermitted to participate in the study.

• Evidence of a clinically significant major congenital anomaly or genetic defect asjudged by the investigator.

• Any known or suspected bleeding disorder in the participant that would pose a riskto venipuncture or intramuscular injection.

• History of any neurologic disorders including encephalopathy, epilepsy, and otherprogressive neurological diseases

• A known or suspected sensitivity or allergy to any components of the investigationalproduct including egg, chicken protein and the antibiotic gentamycin.

• History of severe allergic reaction with generalized urticaria, angioedema, oranaphylaxis.

• Any medical condition in the parent/LAR or child which, in the judgment of theInvestigator, would interfere with or serves as a contraindication to protocoladherence or a participant's parent(s)'/LAR's ability to give informed consent.